Dilon Diagnostics said it signed a deal with GE Healthcare (NYSE:GE) to distribute its GE Discovery NM750b molecular breast imaging system in select locations.
The businesses said the agreement is an “initial step” in an ongoing exploration of ways to provide better healthcare solutions for clinicians and patients.
“We are very pleased to associate with GE Healthcare, a world leader in innovation, in the fight against breast cancer. This relationship will enable us to expand our product portfolio and offer a complete spectrum of BSGI/MBI solutions to better meet the needs of our customers,” Dilon Diagnostics CEO Robert Moussa said in prepared remarks.
The Discovery NM750b system is designed to provide enhanced lesion detectability, which the company said can aid imaging in patients with dense breasts.
“We are excited to make the Discovery NM750b breast imaging system further available and to benefit from Dilon’s global and solid network of sales representatives. GE believes strongly in this advanced technology and the potential for this type of imaging to improve breast cancer diagnosis. Dilon Diagnostics resources will bring further the education and acceptance of molecular breast imaging,” GE Healthcare nuclear imaging global biz manager Nathan Hermony said in a press release.
